Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 23, 2026

Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says

View original at finance.yahoo.com
Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Middle East investors use fossil fuel sales for Bitcoin investment, China uses trade surpluses

    80% confidence

  • Net buying exceeds net selling on Coinbase platform

    80% confidence

  • Institutional investors' thesis of Bitcoin as store of value has not changed despite price volatility

    80% confidence

  • Institutional investors in Hong Kong and UAE are leveraging natural resources to buy and hold Bitcoin

    80% confidence

  • Institutional investors are investing very heavily in adopting blockchain technology for infrastructure

    80% confidence

  • Bitcoin's recent decline is a setup seen multiple times before

    80% confidence

  • Institutional investors have been investing consistently over past five to seven years, not just buying the dip

    80% confidence

  • Bitcoin unlikely to reach $15,000 levels again due to reduced volatility and favorable U.S. administration

    80% confidence

  • 10-year returns: S&P made 2.5x, gold made 3x, Bitcoin made 11,000-15,000x

    80% confidence

Data points we hold from this source

Elf Labs · trademarks copyrights500 count
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com